LTZ Therapeutics

Lift to Zenith with Novel Myeloid Engager Therapeutics

Shenzhen, China · Founded 2022 · $68.0M raised

Headquarters
Shenzhen
Employees
11–50
Founded
2022
Business Model
B2B
Total Funding
$68.0M
Last Round
$38.0M Series BApr 2026
Rounds
4

Totals include recorded grants and other qualifying funding, not just equity. What counts toward funding.

About

LTZ Therapeutics is a clinical-stage, immunotherapy-focused biotechnology company pioneering a novel Myeloid Engager Platform to treat oncology and autoimmune diseases. Founded in 2022 and headquartered in Redwood City, California with operations in Shenzhen, China, the company applies reverse translational science to develop Universal Myeloid Cell Engager (U-MCE)-based therapies targeting unmet clinical needs in cancer immunology.

Summary

LTZ Therapeutics is a Biotech company based in Shenzhen, China, founded in 2022. It has raised $68.0M in total across 4 rounds, most recently a $38.0M Series B round in Apr 2026. Investors include Hillhouse Capital, Qiming VP and Lanchi Ventures.

Tech & App Stack

2 technologies & apps tracked

Every product and vendor across these categories, with where each signal came from.

Create a free account with 25 free credits every month, no card needed, to unlock the full tech & app stack, funding history, and valuations.

Funding History

Series BSeries BApr 2026
$38.0M

Sign up to see all 4 events

Funding: Pre-Seed through Series B. Amounts, valuations, and investors where available.

Investors

Similar Companies

Your company? Embed this profile

Add the live badge to your site — it stays current as your funding data updates.

LTZ Therapeutics on Indexed.vc
<a href="https://indexed.vc/companies/ltz-therapeutics"><img src="https://indexed.vc/api/badge/company/ltz-therapeutics" alt="LTZ Therapeutics on Indexed.vc" width="260" height="76" /></a>